Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention
2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
THOUSAND OAKS, Calif. , March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter...
THOUSAND OAKS, Calif. , March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend...
2 Profitable Stocks with Solid Fundamentals and 1 Facing Headwinds
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.
/Pfizer%20Inc_%20logo%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects
/AMGEN%20Inc_%20HQ%20sign-%20by%20JHVEPhoto%20via%20iStock.jpg)
Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.